On February 4, 2021, VG Acquisition Corp. (VGAC) announced it has entered into a definitive business combination agreement with 23andMe, Inc. (23andMe). 23andMe offers a personalized health and wellness experience and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development. The transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe’s consumer health and therapeutics businesses.

Virgin Group Acquisition Corp. II (VGAC II) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We are primarily focused on effecting a business combination with consumer-facing businesses in the U.S. and Western Europe, with a focus on businesses that provide consumer experiences in the sectors in which Virgin has historically created significant shareholder value, including travel & leisure, financial services, health & wellness, technology & internet-enabled, music & entertainment, media & mobile and renewable energy / resource efficiency.